Huang Chi-Ren, Chuang Hung-Yi, Chen Nai-Ching, Chen Shu-Fang, Hsu Chung-Yao, Chuang Yao-Chung
Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan.
College of Medicine, Chang Gung University, Tao-Yuan 33302, Taiwan.
J Clin Med. 2021 Jul 30;10(15):3380. doi: 10.3390/jcm10153380.
Antiepileptic drugs that can reduce aberrant metabolism are beneficial for patients. Zonisamide (ZNS) is a chemical with antiepileptic and antioxidant activities. Here, we evaluate the efficacy of ZNS therapy on reducing obesity and decreasing risks of vascular diseases and hepatic steatosis. Clinical and metabolic indicators including body weight, body mass index (BMI), serum lipid profiles, glycated hemoglobin (HbA1c), homocysteine, and an inflammatory marker, high-sensitivity C-reactive protein (hs-CRP), were assessed at baseline and at the end of 12 and 24 weeks of treatment. Nonalcoholic fatty liver disease was evaluated using the hepatic steatosis index (HSI). A body weight reduction of ≥5% was observed in 24.6% and 32.8% of patients after 12 and 24 weeks of ZNS treatment, respectively. After adjusting for age, sex, time, and the corresponding dependent variable at baseline, the generalized estimating equation analysis revealed that the body weight, BMI, serum levels of HbA1c, triglycerides, hs-CRP, and the index for HSI were significantly declined. These results suggest that ZNS provides benefits in patients with obesity and metabolic syndrome at high vascular risk.
能够减少异常代谢的抗癫痫药物对患者有益。唑尼沙胺（ZNS）是一种具有抗癫痫和抗氧化活性的化学物质。在此，我们评估ZNS治疗在减轻肥胖以及降低血管疾病和肝脂肪变性风险方面的疗效。在基线以及治疗12周和24周结束时，对包括体重、体重指数（BMI）、血脂谱、糖化血红蛋白（HbA1c）、同型半胱氨酸以及一种炎症标志物——高敏C反应蛋白（hs-CRP）在内的临床和代谢指标进行了评估。使用肝脂肪变性指数（HSI）评估非酒精性脂肪肝病。ZNS治疗12周和24周后，分别有24.6%和32.8%的患者体重减轻≥5%。在对年龄、性别、时间以及基线时相应的因变量进行校正后，广义估计方程分析显示体重、BMI、HbA1c血清水平、甘油三酯、hs-CRP以及HSI指数均显著下降。这些结果表明，ZNS对肥胖和具有高血管风险的代谢综合征患者有益。
